Brief: Obseva Progressing Toward U.S. Phase 3 Trial For Nolasiban In IVF Following Recent FDA Meeting
19/06/2019 07:03
June 19 (Reuters) - Obseva SA OBSN.S :
* OBSEVA PROGRESSING TOWARD U.S. PHASE 3 TRIAL FOR NOLASIBAN
IN
IVF FOLLOWING RECENT FDA MEETING
* COMPANY ANTICIPATES BEGINNING ITS U.S. PHASE 3 CLINICAL
TRIAL
(IMPLANT 3) IN Q4 OF THIS YEAR OR EARLY 2020
* EXPECT TO SUBMIT IMPLANT 3 TRIAL PROTOCOL WITH AN UPDATED
IND IN
Q3 OF 2019
Source text for Eikon: ID:nGNX3lkB2k
Further company coverage: OBSN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Obseva SA
See all newsBrief: Obseva Announces Wind-Down Of Operations And Likely Not Going To Be Able To Satisfy Requirements For Maintaining Its Listing
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary